Table 1.

Expression of PRL-1 and PRL-2 in various tumors and diseased tissues

		PRL-1			PRL-2
Tissue Type/Histopathology	# Samples	Weak (%)	Moderate (%)	Strong (%)	Weak (%)	Moderate (%)	Strong (%)
Bladder
Transitional Cell Carcinoma	7	0	71	29	0	0	100
Sarcomatoid Carcinoma	1	100	0	0	0	0	100
Undifferentiated Carcinoma	1	100	0	0	0	0	100
Hyperplastic Lesion	1	100	0	0	0	0	100
Brain
Alzheimer's	4	25	75	0	25	0	75
Multiple Sclerosis	2	0	0	0	100	0	0
Breast
Invasive Ductal Carcinoma	15	13	40	40	0	7	93
Benign Lesions	2	0	100	0	0	0	100
Cervix
Squamous Cell (LCK)	1	0	100	0	0	0	100
Colon
Adenocarcinoma	5	20	40	40	0	0	100
Metastatic Lesions in Liver	3	0	33	67	0	0	100
Crohn's Disease	2	0	0	100	0	0	100
Coronary Arteries
30-60% Occlusion	3	33	0	0	0	33	33
60-90% Occlusion	2	0	0	0	0	50	0
Heart
Heart Disease	7	43	0	0	14	86	0
Kidney
Renal Cell Carcinoma	13	38	31	8	8	8	84
Liver
Hepatocellular Carcinoma	4	0	100	0	0	0	100
Hepatitis	2	100	0	0	0	50	50
Steatosis	2	50	50	0	0	50	50
Lung
Non Small Cell Lung Cancer	8	0	37	63	0	12	88
Lymph Node
B-Cell Lymphoma	4	0	0	100	0	0	100
Hodgkin Lymphoma	1	0	0	100	0	0	100
Metastatic Lymphoma in Testes	1	0	0	100	0	0	100
Ovary
Epithelial Tumor	17	41	35	0	6	12	82
Dysgerminoma	1	0	100	0	0	0	100
Pancreas
Exocrine Tumor	12	0	8	92	0	0	100
Endocrine Tumor	2	0	0	100	0	0	100
Diabetic	8	0	0	100	0	0	100
Prostate
Adenocarcinoma	28	25	25	50	0	0	100
Skeletal Muscle
Diabetic	4	0	50	0	0	25	75
Skin
Basal Cell Carcinoma	1	100	0	0	0	0	100
Spleen
Chronic Lymphocytic Leukemia	1	100	0	0	0	100	0
Chronic Myelogenous Leukemia	1	0	0	100	0	0	100
Diabetic	3	0	67	0	0	33	67
Stomach
Adenocarcinoma	4	0	0	100	0	0	100
Leiomyosarcoma	1	0	0	100	0	0	100
Testis
Germ Cell Tumor	4	0	50	50	0	0	100
Uterus
Adenocarcinoma	6	33	50	0	0	17	83
Sarcoma (MMMT)	1	0	0	100	0	0	100
Vasculature (Multi Tumor Tissues)	38	21	32	45	0	5	95
Stroma (Multi Tumor Tissues)	90	41	29	17	0	12	88

Abbreviations: LCK = Large Cell Keratinizing; MMMT = Malignant Mixed Mullerian Tumor